Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Current Report · Items 8.01, 9.01 · 8-K

NovoCure Limited

NVCRNASDAQEQUITYCurrent

Other Events

Item 8.01 Other Events. In mid-August 2026, NovoCure Limited (the "Company," "we," or "us") through a subsidiary, became aware of unauthorized access to some of its information systems. Upon detecting the unauthorized access, the Company activated its cybersecurity response plan, implemented containment measures, and initiated an internal investigation of the event.…

Filed Sep 1, 2026Accepted Sep 1, 2026, 7:00 AM EDTCIK 1645113Accession 0001645113-26-000065
Share

Company context

Current securities

Recent company filings

  1. Regulation FD DisclosureNov 9, 2026
  2. S-8 filingOct 29, 2026
  3. Results of Operations and Financial ConditionOct 29, 2026
  4. 10-Q filingOct 29, 2026
  5. Regulation FD DisclosureOct 1, 2026

Registered securities in this filing

NovoCure Limited · 8-K · Filed 2026-09-01

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Ordinary Shares, no par value

Symbol
NVCR
Exchange
NASDAQ
Classification
COMMON
Status
Current
Filing context

Context: c-1

Dimensions: Not supplied

Accession 000164511326000065 · 1 registered-security cover member

Read the exact SEC filing ↗

Disclosure sections

Items 8.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 8.01Item 8.01 - Other Events
Item 8.01 Other Events. In mid-August 2026, NovoCure Limited (the "Company," "we," or "us") through a subsidiary, became aware of unauthorized access to some of its information systems. Upon detecting the unauthorized access, the Company activated its cybersecurity response plan, implemented containment measures, and initiated an internal investigation of the event. The Company also engaged independent cybersecurity forensic experts to assist with the investigation, including reviewing the exposed data that was accessed. Based on the investigation to date, the Company determined that the exposed data included: internal Company patient ID numbers for over 1,400 U.S. patient records (these ID numbers are only used internally and no patient names or other identifying data for these was exposed); patient data for fewer than 50 other patients in the western U.S. that included additional identifying information; general contact information for healthcare providers we work with; and general contact information for Novocure employees, such as their job titles and phone numbers. No access to any of our medical treatment devices was obtained, our ability to operate has not been compromised and all of our systems are fully functional. The Company takes its obligation to safeguard privacy and security of its patients’ data very seriously. The Company continues to evaluate applicable regulatory and legal notification requirements and will make all required notifications based on its findings, including to impacted patients. At this time, we do not believe that this cybersecurity incident will have a material impact or reasonably likely material impact on our financial condition and results of operations; however, at the time of this filing we are continuing to ascertain additional information regarding this incident. If additional information is obtained whereby we determine this cybersecurity incident will have a material impact or reasonably likely material impact on our financial condition and results of operations, we undertake to file an amendment to this Form 8-K filing under Item 1.05 containing such information within four business days after we, without unreasonable delay, determine such information, or within four business days after such information becomes available. Forward-Looking Statements In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, clinical study progress, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, coverage, collections from third-party payers and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and terms of similar meaning. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, environmental, regulatory and political conditions and other more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on February 26, 2026, and subsequent flings with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Novocure does not intend to update publicly any forward-looking statement, except as required by law. Any forward-looking statements herein speak only as of the date hereof. The Private Securities Litigation Reform Act of 1995 permits this discussion.

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.